Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKM-080301 in Advanced Hepatocellular Carcinoma
NCT02191878Phase 2Completed
- Sponsor
- Arbutus Biopharma Corporation
- Start
- Jun 2014
- Primary completion
- May 2016
- Modality
- Lipid-based Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 6
01
Overview
A Phase 2 trial of TKM-080301 in hepatocellular carcinoma (HCC), sponsored by Arbutus Biopharma Corporation. Started Jun 2014; status: completed.
02
Drugs
TKM-080301
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02191878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02191878.